ImmunityBio, Inc. (NASDAQ:IBRX) Shares Purchased by E Fund Management Co. Ltd.

E Fund Management Co. Ltd. grew its holdings in shares of ImmunityBio, Inc. (NASDAQ:IBRX) by 32.9% in the 4th quarter, Holdings Channel reports. The fund owned 38,900 shares of the company’s stock after acquiring an additional 9,622 shares during the period. E Fund Management Co. Ltd.’s holdings in ImmunityBio were worth $100,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Stephens Inc. AR purchased a new position in ImmunityBio in the fourth quarter valued at about $26,000. Captrust Financial Advisors purchased a new position in shares of ImmunityBio during the 3rd quarter valued at approximately $41,000. Virtu Financial LLC acquired a new stake in shares of ImmunityBio during the third quarter worth approximately $51,000. Maia Wealth LLC acquired a new stake in shares of ImmunityBio during the fourth quarter worth approximately $37,000. Finally, Schechter Investment Advisors LLC bought a new stake in shares of ImmunityBio in the fourth quarter worth $38,000. 8.58% of the stock is owned by hedge funds and other institutional investors.

ImmunityBio Stock Performance

Shares of NASDAQ:IBRX opened at $3.00 on Monday. The company’s fifty day moving average is $3.05 and its two-hundred day moving average is $3.70. ImmunityBio, Inc. has a 1-year low of $2.28 and a 1-year high of $10.53. The stock has a market capitalization of $2.09 billion, a price-to-earnings ratio of -3.26 and a beta of 0.82.

ImmunityBio (NASDAQ:IBRX) last released its quarterly earnings data on Monday, March 3rd. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.11. The business had revenue of $7.55 million for the quarter, compared to analyst estimates of $8.74 million. Sell-side analysts expect that ImmunityBio, Inc. will post -0.92 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on IBRX shares. D. Boral Capital reissued a “buy” rating and set a $30.00 price objective on shares of ImmunityBio in a report on Friday, February 28th. HC Wainwright began coverage on ImmunityBio in a research note on Thursday. They issued a “buy” rating and a $8.00 price target for the company. Finally, BTIG Research assumed coverage on ImmunityBio in a research note on Friday, January 10th. They set a “buy” rating and a $6.00 price objective on the stock. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $12.19.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.